- Report
- September 2023
- 100 Pages
Global
From €5719EUR$5,950USD£4,904GBP
- Report
- November 2023
- 175 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Clinical Trials
- April 2024
- 550 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1922EUR$2,000USD£1,648GBP
- Report
- October 2023
- 190 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- March 2019
- 124 Pages
Global
From €1322EUR$1,375USD£1,133GBP
€2643EUR$2,750USD£2,267GBP
- Report
- June 2018
- 99 Pages
Global
From €5719EUR$5,950USD£4,904GBP
- Report
- March 2023
- 115 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- September 2022
- 162 Pages
Middle East, Africa
From €2018EUR$2,100USD£1,731GBP
€2883EUR$3,000USD£2,473GBP
- Report
- September 2022
- 152 Pages
From €2018EUR$2,100USD£1,731GBP
€2883EUR$3,000USD£2,473GBP
- Report
- September 2022
- 157 Pages
North America
From €2018EUR$2,100USD£1,731GBP
€2883EUR$3,000USD£2,473GBP
- Report
- September 2022
- 181 Pages
Europe
From €2018EUR$2,100USD£1,731GBP
€2883EUR$3,000USD£2,473GBP
- Report
- September 2022
- 185 Pages
Asia Pacific
From €2018EUR$2,100USD£1,731GBP
€2883EUR$3,000USD£2,473GBP
- Report
- June 2022
- 259 Pages
Global
From €3061EUR$3,185USD£2,625GBP
€4373EUR$4,550USD£3,750GBP
- Report
- June 2022
- 117 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- February 2022
- 308 Pages
Global
From €9131EUR$9,500USD£7,830GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3124EUR$3,250USD£2,679GBP
- Report
- August 2022
- 113 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Newsletter
- May 2024
Global
From €1010EUR$1,126USD£896GBP
- Report
- August 2018
- 17 Pages
Global
From €9612EUR$10,000USD£8,242GBP
Cetuximab is a monoclonal antibody used in the treatment of lung cancer. It is used in combination with chemotherapy to treat non-small cell lung cancer (NSCLC). Cetuximab works by targeting the epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. This helps to slow down or stop the growth of cancer cells. Cetuximab is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC in combination with chemotherapy. It is also approved for the treatment of metastatic colorectal cancer.
Cetuximab is available in both intravenous and subcutaneous formulations. It is typically administered in combination with chemotherapy drugs such as cisplatin, carboplatin, and paclitaxel. Common side effects of cetuximab include skin rash, fatigue, nausea, and diarrhea.
Some companies in the Cetuximab market include Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. Show Less Read more